Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday

Key Points

• Phathom Pharmaceuticals (NASDAQ:PHAT) is scheduled to release its Q2 2025 earnings on Thursday, August 7th, with analysts predicting a loss of ($0.76) per share and revenue of $35.58 million.
• AQR Capital Management recently increased its stake in Phathom Pharmaceuticals by 508.2%, indicating growing institutional interest as 99.01% of the stock is owned by institutional investors and hedge funds.
• Analysts have mixed ratings on the stock, with price targets ranging from $5.00 to $28.00, creating an average target price of $17.50 and a consensus rating of "Buy."

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $35.58 million for the quarter.

Phathom Pharmaceuticals Stock Performance

Phathom Pharmaceuticals stock traded up $0.33 during midday trading on Monday, reaching $8.68. 176,144 shares of the company's stock were exchanged, compared to its average volume of 1,814,812. Phathom Pharmaceuticals has a 52 week low of $2.21 and a 52 week high of $19.71. The firm has a market cap of $605.71 million, a price-to-earnings ratio of -1.66 and a beta of 0.45. The stock's 50-day simple moving average is $8.33 and its 200 day simple moving average is $6.19.

Analysts Set New Price Targets

PHAT has been the subject of several research analyst reports. Guggenheim decreased their price target on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Craig Hallum boosted their price target on shares of Phathom Pharmaceuticals from $12.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, June 9th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Phathom Pharmaceuticals in a research note on Monday, June 9th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, June 6th. Finally, The Goldman Sachs Group lowered their target price on shares of Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $17.50.

Institutional Investors Weigh In On Phathom Pharmaceuticals

An institutional investor recently raised its position in Phathom Pharmaceuticals stock. AQR Capital Management LLC lifted its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 508.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 107,399 shares of the company's stock after acquiring an additional 89,741 shares during the quarter. AQR Capital Management LLC owned approximately 0.15% of Phathom Pharmaceuticals worth $673,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 99.01% of the company's stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.